IMMUSANT
ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy. ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.
IMMUSANT
Industry:
Biotechnology Health Diagnostics Therapeutics
Founded:
2011-06-08
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.immusant.com
Total Employee:
11+
Status:
Closed
Contact:
617-299-8399
Email Addresses:
[email protected]
Total Funding:
72.78 M USD
Technology used in webpage:
Domain Not Resolving YouTube
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF T1D Fund
JDRF T1D Fund investment in Venture Round - ImmusanT
ARCH Venture Partners
ARCH Venture Partners investment in Series C - ImmusanT
Vatera Healthcare Partners
Vatera Healthcare Partners investment in Series C - ImmusanT
Vatera Healthcare Partners
Vatera Healthcare Partners investment in Series B - ImmusanT
Vatera Healthcare Partners
Vatera Healthcare Partners investment in Series A - ImmusanT
